Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide as first-line and 2nd-line treatment in patients with low risk, non-deletion 5q myelodysplastic syndromes.

Next Previous
Trial Profile

Lenalidomide as first-line and 2nd-line treatment in patients with low risk, non-deletion 5q myelodysplastic syndromes.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use

Most Recent Events

  • 12 Jan 2015 According to a Celgene Corporation media release, submission of lenalidomide in the U.S. and discussion of lenalidomide for non-deletion 5q myelodysplastic syndrome with regulatory authorities in additional geographies is expected in 2015.
  • 16 Sep 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top